Randomised Study of Interferon-free Treatment for Recently Acquired Hepatitis C in PWID and People With HIV Coinfection.

NCT ID: NCT02625909

Last Updated: 2021-11-24

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 222 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-03-09
• Study Completion Date: 2020-03-23

Brief Summary

The aim of the study is to determine if treatment for recently acquired hepatitis C infection (with or without HIV coinfection) can be shortened when treating with the interferon-free therapy sofosbuvir/velpatasvir (SOF/VEL).

SOF/VEL is a new treatment for hepatitis C called direct acting antiviral which targets the hepatitis C virus replication cycle and has been shown in phase II studies in chronic HCV to be highly effective (SVR12 >95%) when given for 12 weeks.

Data has shown that treatment can be shortened when treating recently acquired HCV with interferon containing treatments. It is not known whether treatment with SOF/VEL can be shortened.

This study aims to find out if treatment for 6 weeks with open-label SOF/VEL is equivalent to treatment for 12 weeks with SOF/VEL in participants with recently acquired hepatitis C infection. The project is a randomised study where both participants and investigators would not find out the treatment duration of the participants until week 6 of treatment.

Detailed Description

Globally, 3-4 million new HCV infections are estimated to occur annually. People who inject drugs (PWID) represent one of the groups at highest risk of transmitting and acquiring infection with the majority of new (60%) and existing (80%) infections in developed countries occur in this population with HCV antibody prevalence estimated at 67% (60-80%). HIV-positive men-who-have-sex-with-men (MSM) are another high risk group for HCV acquisition.

Direct acting antivirals (DAA) has changed the treatment landscape for individuals with chronic HCV infection with interferon-free therapy offering high effectiveness and tolerability, even in "difficult-to-treat" populations.

Given the burden of HCV-related disease among PWID and HIV-positive MSM, strategies to enhance HCV assessment, treatment and prevention in these groups are urgently needed. Much of what is known about the timing of treatment initiation, regimen choice and duration of therapy in acute HCV infection comes from small observational studies and randomized controlled (randomly assigned into one or other of the different treatment groups)trials in selected populations with limited data on treatment in PWID and HIV co-infection. With recent rapid advances in HCV treatments, management strategies for acute HCV will evolve rapidly over the next few years.

The REACT study will compare the efficacy and safety of open-label SOF/VEL administered for 6 or 12 weeks in individuals with recent HCV infection. Participants will be randomised into receiving 6 weeks or 12 weeks treatment. Both investigators and participants will be blinded to the treatment duration until week 6 of treatment. The role and activity of DAA regimens in acute HCV infection requires evaluation, with the potential to be given as highly effective, short course interferon-sparing regimens, maximising acceptability to patients, encouraging uptake of treatment, limiting further transmission and preventing progression to chronic liver disease.

Conditions

Hepatitis C

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Drug: SOF/VEL for 6 weeks

Open-label SOF/VEL 400mg/100mg co-formulated tablet once daily will be given to participants who are randomised into the short treatment duration arm (A) for 6 weeks.

Group Type: EXPERIMENTAL

SOF/VEL for 6 weeks

Intervention Type: DRUG

Open-label SOF/VEL 400mg/100mg once daily to be given to participants randomised to Arm A (6 weeks short treatment duration).

Drug: SOF/VEL for 12 weeks

Open-label SOF/VEL 400mg/100mg co-formulated tablet once daily will be given to participants who are randomised into the standard treatment duration arm (B) for 12 weeks.

Group Type: EXPERIMENTAL

SOF/VEL for 12 weeks

Intervention Type: DRUG

Open-label SOF/VEL 400mg/100mg once daily to be given to participants randomised to Arm B (12 weeks standard treatment duration).

Interventions

SOF/VEL for 6 weeks

Open-label SOF/VEL 400mg/100mg once daily to be given to participants randomised to Arm A (6 weeks short treatment duration).

Intervention Type: DRUG

SOF/VEL for 12 weeks

Open-label SOF/VEL 400mg/100mg once daily to be given to participants randomised to Arm B (12 weeks standard treatment duration).

Intervention Type: DRUG

Other Intervention Names

sofosbuvir (Sovaldi)/velpatasvir; sofosbuvir (Sovaldi)/velpatasvir

Eligibility Criteria

Inclusion Criteria

1. Participants have voluntarily signed the informed consent form.

2. 18 years of age or older.

3. Detectable HCV RNA at screening (>10,000 IU/ml), and in the opinion of the investigator is unlikely to demonstrate spontaneous viral clearance

4. HCV genotypes 1-6.

5. HBsAg negative

6. Compensated liver disease (Child-Pugh A)

7. Negative pregnancy test at baseline (females of childbearing potential only).

8. Medically stable on the basis of physical examination, medical history and vital signs

9. Adequate English to provide reliable responses to the study questionnaires

10. All fertile males and females must be using effective contraception during treatment and during the 30 days after treatment end.

11. Recently acquired HCV infection (estimated duration of infection ≤12 months)*

Recently acquired HCV infection as defined by:

A) i) First anti-HCV Ab or HCV RNA positive within the previous 3 months and ii) Documented anti-HCV Ab negative within the 12 months prior to anti-HCV antibody positive result

OR

B) i) First anti-HCV Ab or HCV RNA positive within the previous 3 months and ii) Acute clinical hepatitis [jaundice or alanine aminotransferase (ALT)] > 10 X ULN) within the previous 6 months prior to first positive HCV antibody or HCV RNA, with no other cause of acute hepatitis identifiable

OR

C) For cases of recent HCV reinfection the following criteria are required:

Documented prior HCV antibody positive with HCV RNA negative on at least 2 occasions 6 months apart AND new HCV RNA positive within the previous 6 months

*Estimated duration of infection based on midpoint between last antibody negative or HCV RNA and first antibody positive or HCV RNA in the case of seroconversion and 6 weeks prior to date of maximum ALT in the case of acute hepatitis.

If co-infection with HIV is documented, the subject must meet the following criteria:

1. Antiretroviral (ARV) untreated for >8 weeks preceding screening visit with cluster of differentiation 4 (CD4) T cell count >500 cells/mm3 OR

2. On a stable ARV regimen for >8 weeks prior to screening visit, with CD4 T cell count >200 cells/mm3 and an undetectable plasma HIV RNA level.

• Suitable ARV include:

• Tenofovir (TDF) and tenofovir alafenamide (TAF)
• Emtricitabine (FTC)
• Rilpivirine
• Dolutegravir
• Elvitegravir/cobicistat
• Contraindicated ARV include:

• Efavirenz 50% reduction in velpatasvir (GS-5816) exposure
• Didanosine
• Zidovudine
• Tipranavir Other ARV agents may be permissible at the time of study commencement pending further drug-drug interaction studies; please discuss with Study Principal Investigator.

Exclusion Criteria

1. History of any of the following:

1. Clinically significant illness (other than HCV) or any other major medical disorder that may interfere with the participant treatment, assessment or compliance with the protocol; participants currently under evaluation for a potentially clinically significant illness (other than HCV) are also excluded.

2. History of chronic pulmonary disease associated with functional limitation, severe cardiac disease, major organ transplantation or other evidence of severe illness, malignancy, or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study

3. Solid organ transplant

4. Malignancy within 5 years prior to screening, with exception of specific cancers that may have been cured by surgical resection (basal cell skin cancer, etc.). Subjects under evaluation for possible malignancy are also excluded.

5. Significant drug allergy (such as anaphylaxis or hepatotoxicity).

2. Subject shows evidence of significant liver disease in addition to hepatitis C, which may include but is not limited to drug- or alcohol-related cirrhosis, autoimmune hepatitis, hemochromatosis, Wilson's disease, non-alcoholic steatohepatitis (NASH), or primary biliary cirrhosis

3. Subject has known cirrhosis

4. Any of the following lab parameters at screening:

1. Direct bilirubin > 1.5 x ULN

2. Platelets < 50,000/μL

3. Creatinine clearance (CLcr) < 60 mL/min

4. Haemoglobin < 11 g/dL for females ; < 12 g/dL for males

5. Albumin < 30g/L

5. Pregnant or nursing female.

6. Use of prohibited concomitant medications as described in section 5.2 in the protocol

7. Chronic use of systemically administered immunosuppressive agents (e.g. prednisone equivalent > 10 mg/day)

8. Known hypersensitivity to velpatasvir, sofosbuvir or formulation excipients.

9. Therapy with any anti-neoplastic or immunomodulatory treatment (including supraphysiologic doses of steroids and radiation) ≤6 months prior to the first dose of study drug.

10. Any investigational drug ≤6 weeks prior to the first dose of study drug.

11. Previous failure of therapy with sofosbuvir or an non-structural protein 5A (NS5A) inhibitor prior to the first dose of study drug.

12. Ongoing severe psychiatric disease as judged by the treating physician.

13. Frequent injecting drug use that is judged by the treating physician to compromise treatment safety.

14. Inability or unwillingness to provide informed consent or abide by the requirements of the study.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Kirby Institute

OTHER_GOV

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Gail V Matthews, MbChB, PhD

Role: PRINCIPAL_INVESTIGATOR

The Kirby Institute, University of New South Wales Australia, Sydney, New South Wales, Australia, NSW 2052

Locations

Johns Hopkins University

Baltimore, Maryland, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

Kirketon Road Centre

Sydney, New South Wales, Australia

St. Vincent's Hospital

Sydney, New South Wales, Australia

The Kirby Institute, University of New South Wales Australia

Sydney, New South Wales, Australia

Royal Adelaide Hospital

Adelaide, South Australia, Australia

The Alfred Hospital

Melbourne, Victoria, Australia

Royal Melbourne Hospital

Melbourne, Victoria, Australia

St Paul's Hospital

Vancouver, British Columbia, Canada

Cool Aid Community Health Centre

Victoria, British Columbia, Canada

Toronto General Hospital

Toronto, Ontario, Canada

Centre Hospitalier de l' Universite de Montreal

Montreal, Quebec, Canada

Praxis Dr Cordes

Berlin, , Germany

Zentrum für Infektiologie Berlin-Prenzlauer Berg

Berlin, , Germany

University Hospital of Bonn

Bonn, , Germany

Infektio-Research GmbH

Frankfurt, , Germany

Academic Medical Centre, University of Amsterdam

Amsterdam, , Netherlands

Auckland City Hospital

Auckland, , New Zealand

University Hospital Zurich

Zurich, Canton of Zurich, Switzerland

Bern University Hospital

Bern, , Switzerland

Fondazione Epatocentro Ticino

Lugano, , Switzerland

Brighton & Sussex University Hospitals NHS Trust

Brighton, Brigton and Hove, United Kingdom

Pennine Acute Hospitals NHS Trust

Manchester, Lancashire, United Kingdom

Royal Free Hospital

London, , United Kingdom

Chelsea & Westminster Hospital

London, , United Kingdom

Countries

United States; Australia; Canada; Germany; Netherlands; New Zealand; Switzerland; United Kingdom

References

Carson JM, Barbieri S, Cunningham E, Mao E, van der Valk M, Rockstroh JK, Hellard M, Kim A, Bhagani S, Feld JJ, Gane E, Thurnheer MC, Bruneau J, Tu E, Dore GJ, Matthews GV, Martinello M; REACT study group. Sexual and drug use risk behaviour trajectories among people treated for recent HCV infection: the REACT study. J Int AIDS Soc. 2023 Sep;26(9):e26168. doi: 10.1002/jia2.26168.

Reference Type: DERIVED

PMID: 37675828 (View on PubMed)

Matthews GV, Bhagani S, Van der Valk M, Rockstroh J, Feld JJ, Rauch A, Thurnheer C, Bruneau J, Kim A, Hellard M, Shaw D, Gane E, Nelson M, Ingiliz P, Applegate TL, Grebely J, Marks P, Martinello M, Petoumenos K, Dore GJ; REACT study group; Protocol Steering Committee; Coordinating Centre; Site Principal Investigators. Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection. J Hepatol. 2021 Oct;75(4):829-839. doi: 10.1016/j.jhep.2021.04.056. Epub 2021 May 21.

Reference Type: DERIVED

PMID: 34023350 (View on PubMed)

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

VHCRP1401

Identifier Type: -

Identifier Source: org_study_id